Egrie, Joan C.

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine

Erythropoietin and Anemia TreatmentDialysis and Renal Disease Management

Cited by 1,930

Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial

Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine

Erythropoietin and Anemia TreatmentBiosimilars and Bioanalytical Methods

Cited by 795

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A. (2003) · Experimental Hematology

Erythropoietin and Anemia TreatmentBiosimilars and Bioanalytical Methods

Cited by 421